Recursion Pharmaceuticals, Inc. (RXRX)

Recursion Pharmaceuticals is trading in the lower part of its yearly range and under its 50-day average, after a quarter in which revenue grew sharply but losses remained wide. The stock closed at $3.59 on November 11, 2026, which sits 5.17% below its 50-day simple moving average of $3.79 and 2.93% above its 200-day average of $3.49. The price is at the middle of a range set by a 52-week low of $2.77 and a high of $5.24, so the next few sessions will test whether the 200-day average holds as support. For investors the question is whether the company's revenue growth can narrow a loss that still runs well ahead of sales.

Recursion reported adjusted earnings of -$0.22 per share on November 2, 2026, against an analyst estimate of -$0.23, so the loss was smaller than expected. The earnings record shows four beats and two misses, yet the share price was lower in the first session after five of the six reports.

The stock trades at a price-to-sales ratio of 28.10, compared with a sector median of 3.4, which is 726.5% above that median. Reported earnings per share over the last twelve months were -$0.86, so the price-to-earnings ratio is not meaningful. The net profit margin is -697.13% and return on equity is -48.72%, both weak next to a sector median return on equity of 7.3%. The balance sheet is less of a concern, with debt-to-equity at 0.08.

Insiders sold $13.7M of stock over the last 18 months across 42 sales, and recorded no open-market purchases over the same period. Such sales are often planned in advance or made to cover tax on vesting shares, so they carry less weight than purchases would. The company describes itself as a clinical-stage TechBio business that uses automation, artificial intelligence and machine learning to identify drug candidates, so its value depends on pipeline progress that has yet to be proven in later-stage results.

The base case is that the stock stays in a range between the 200-day average and the 50-day average while the company keeps reporting losses. Analyst targets range from $4.00 to $10.00, with a median of $7.00, which is 95.0% above the price, so the analysts' view assumes a far higher value than the market currently gives. Three of the seven analysts rate the stock Buy, four rate it Hold and none rate it Sell. Analysts expect revenue this fiscal year to shrink by 44.6%, which is a key risk to any forecast built on the recent quarter.

Support sits first at the 200-day simple moving average of $3.49, which the price is currently holding above. Below it is the 52-week low of $2.77, the lowest trade in the past year and the level a further decline would reach next. Resistance begins at the 20-day exponential moving average of $3.78, closely followed by the 50-day simple moving average of $3.79. The 52-week high of $5.24 is the furthest level above the price and would require a sustained rally to reach.